Vimab Group AB (OSTO:VIMAB) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:VIMAB Vimab Group AB OSTO:VIMAB
47 GF Score
Price kr2.89
GF Value kr5.95
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Vimab Group AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Vimab Group AB is: High Risk: High uncertainty.

Vimab Group AB  (OSTO:VIMAB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Vimab Group AB Risk Assessment Related Terms

OSTO:VIMAB vs VRSK, EFX, BAH: Risk Assessment Comparison

For the Consulting Services subindustry, Vimab Group AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vimab Group AB Risk Assessment vs Business Services Industry

For the Business Services industry and Industrials sector, Vimab Group AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Vimab Group AB's Risk Assessment falls into.


OSTO:VIMAB
47GF Score
Vimab Group AB OSTO:VIMAB
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vimab Group AB (OSTO:VIMAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vimab Group AB stock appears to be undervalued. The current stock price of kr2.89 is trading 51.4% below its estimated GF Value™ of kr5.95. GuruFocus considers Vimab Group AB to be Possible Value Trap.

Key valuation signals for OSTO:VIMAB:

  • Risk Assessment:
  • GF Value™: kr5.95 vs. price of kr2.89 (51.4% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the OSTO:VIMAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vimab Group AB Business Description

Address Malmskillnadsgatan 40A, Stockholm, SWE, 111 57
Vimab Group AB is a Nordic company helping companies with transformation and improvement initiatives. It offers services including Interim management, Executive search.
47GF Score

Get the complete analysis for OSTO:VIMAB

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.89
Price
kr5.95
GF Value